Altimmune, Inc. (NASDAQ:  ALT) Securities Fraud Class Action

Altimmune, Inc. (NASDAQ: ALT) Securities Fraud Class Action

CompanyAltimmune, Inc.
CourtUnited States District Court for the District of Maryland
Case Number8:25-cv-02581
JudgeHonorable Theodore D. Chuang
Class PeriodAugust 10, 2023 through June 25, 2025
Security TypeSecurities

LEAD PLAINTIFF DEADLINE IS OCTOBER 6, 2025.

If you have suffered losses and would like to discuss your rights, please fill out this form or you may contact Jonathan Naji, Esq. at (484) 270-1453 or via e-mail at [email protected].

Case Background:
A class action lawsuit was filed on behalf of those who purchased or otherwise acquired Altimmune, Inc. (“Altimmune”) (NASDAQ: ALT) securities between August 10, 2023 and June 25, 2025, inclusive (the “Class Period”).

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects.  Specifically, Defendants misrepresented and/or failed to disclose that: (1)  Altimmune created a false impression that it had reliable information pertaining to the results of its IMPACT Phase2b MASH trial, which was evaluating a treatment for fibrosis reduction; (2) Altimmune did not meet an important statistical significance marker relating to the fibrosis reduction primary endpoint; (3) throughout the trial, Altimmune had consistently touted inflated expectations for positive results from the IMPACT Phase 2b MASH trial, while concealing that the placebo group reported higher responses; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

What is a Lead Plaintiff?

A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case.  Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

Complete this form with your transactions in Altimmune, Inc. securities between August 10, 2023 and June 25, 2025.

Click Here to Print PDF of this Form

    Submit Your Information
    SUBMIT YOUR INFORMATION
    * Denotes required field
    Phone Country code
    Purchase Information
    Sales Information
    Did you purchase shares of Altimmune, Inc. prior to the Class Period?
    Are you a current or former employee of Altimmune, Inc.?
    The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. READ MORE
    I agree to the KTMC disclaimer
    I would like to receive new case alerts by email
    Scroll to Top